

# Synairgen PLC

10:00 17 Oct 2020

## Small Cap Movers: 'Ten-baggers' Synairgen, Alien Metals keep up impressive share price runs

Synairgen PLC (LON:SNG) this week completed an £80mln share placing to support its lead drug through final-stage coronavirus (COVID-19) clinical trials.

Nothing unusual there - except for the fact that a year ago the business was valued at just over £14mln. Now it's worth £301mln.

The shares have zoomed up by 2,082% to 194p over the past twelve months, earning Synairgen entry to the 'ten-bagger' club of high growth stocks that have risen at least ten-fold in a short space of time.

The latest cash injection will allow the life sciences group to fund a phase III trial of SNG001, an inhaled interferon-beta powder. It will also allow it to ramp up production next year to 100,000 treatment courses a month.

Also in the 'ten-bagger' club is Alien Metals Ltd (LON:UFO), which continued to enjoy its otherworldly run this week with a 34% jump to 2p.

The stock has rocketed 1,830% higher since July with the silver price providing the catalyst - this and a greater investor appreciation of the true potential of Alien's Elizabeth Hill project in Western Australia.

Polarean Imaging PLC (LON:POLX) - up 42% this week to 69p - hasn't quite scaled the same heights but you'd still have tripled your initial investment had you invested in the stock just six months ago, with the share price driven higher by a steady stream of positive news flow.

The med-tech group, which has created a drug-device combo that allows doctors to scrutinise lungs using MRI, this week signed up the world-famous MD Anderson Cancer Center in Texas as its latest research client.

Turning to the wider market, the AIM-All Share dipped 1% over the week to 977, but still outperformed the FTSE 100, which was down 2% to 5,890.

In the mining sector, GCM Resources PLC (LON:GCM) climbed 38% higher to 14p after establishing a joint venture with China's NFC for the Phulbari coal project in Bangladesh.

Elsewhere, surveillance systems developer Petards Group PLC (LON:PEG) pushed 26% higher to 8p on the back of a new contract to supply software to trains operated by Great Western Railway.

Among the fallers, security and cleaning specialist STM Group PLC (LON:STM) dropped 26% to 26p after warning full-year profits will be hit by weak trading, but it said it should recover next year.

In the online retail space, ASOS PLC (LON:ASC) shed 14% to 4,688p despite posting a four-fold increase in profits after a strong lockdown performance. The decline marks an intensification of profit-taking after shares rallied almost five-

**Price:** 161

**Market Cap:** £265.13 m

### 1 Year Share Price Graph



October 2019    May 2020    October 2020

### Share Information

**Code:** SNG

**Listing:** AIM

<b>52 week</b>	<b>High</b>	<b>Low</b>
	<b>258.456</b>	<b>5.46734</b>

**Sector:** Pharma & Biotech

**Website:** [www.synairgen.com](http://www.synairgen.com)

### Company Synopsis:

*Synairgen is a drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on severe asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic Key Opinion Leader network to discover and develop novel therapies for respiratory disease. &nbsp;.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

fold from their post-pandemic nadir.

Meanwhile, hostels operator Safestay PLC (LON:SSTY) dipped 8% to 11p after announcing the temporary closure of eight hostels, reducing bed capacity across the chain to 45% of normal. FTSE 250-listed competitor Hostelworld forecast a slow recovery this week.

Upcoming are two new issues that should offer a little variety to the normal diet of natural resources, tech and biotech stocks found on AIM.

According to reports, Chrystal Capital Partners plans to have Verdite, Europe's largest cannabis-focused private equity fund, up and running by the end of the year.

MailBox REIT, meanwhile, is taking a completely new route to market. Rather than being quoted on the LSE it is expected to become the very first listing on the IPSX, the world's first regulated stock exchange dedicated solely to property.

The single-asset real estate investment trust owns the Mailbox in Birmingham, a 698,000 square-foot office, retail and leisure development.

Making its market debut in early November, the trust is raising £62.5m, giving it a market capitalisation of £116m at £1 a share. The Birmingham building has been independently valued at £179m.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).